| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;92:2480-2487.)
© 1995 American Heart Association, Inc.
Articles |
From the Cardiovascular Division, Beth Israel Hospital, Boston, Mass (D.J.C., C.A.S., K.K.L.H., D.S.B.); the Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass (D.J.C., R.B.S.); Yale School of Medicine, New Haven, Conn (H.M.K., M.C.); Arizona Heart Institute, Phoenix (R.R.H.); Johns Hopkins Hospital, Baltimore, Md (J.A.B.); Lenox Hill Hospital, New York, NY (J.W.M.); Jefferson Medical College, Philadelphia, Pa (M.P.S.); the University of Pittsburgh (Pa) (K.D.); and the Washington (DC) Cardiology Center (M.B.L.).
Correspondence to David J. Cohen, MD, MSc, Cardiovascular Division, Beth Israel Hospital, 330 Brookline Ave, Boston, MA 02215. E-mail djc@hsph.harvard.edu.
Background Coronary stenting has been shown to improve initial success, reduce angiographic restenosis, and reduce the need for repeat revascularization compared with conventional balloon angioplasty (PTCA). Although previous studies have demonstrated that initial hospital costs for stenting are considerably higher than those for conventional PTCA, the impact of coronary stenting on long-term medical care costs remains unknown.
Methods and Results Between January 1991 and June 1993, 207
consecutive patients with symptomatic coronary
disease requiring revascularization of a single
coronary lesion were randomized to receive initial treatment by
either PTCA (n=105) or Palmaz-Schatz coronary stent
implantation (n=102) in the multicenter STRESS trial. Detailed resource
utilization and cost data were collected for each patient's initial
hospitalization and for any subsequent hospital visits for 1 year after
randomization. Compared with conventional angioplasty, coronary
stenting resulted in additional catheterization
laboratory costs, increased vascular complications, and longer length
of stay. Initial hospital costs were thus
$2200 higher for stenting
than for PTCA ($9738±3248 versus $7505±5015;
P<.001).
Over the first year of follow-up, however, patients assigned to
initial stenting were less likely to require rehospitalization for a
cardiac condition and underwent fewer subsequent
revascularization procedures. Follow-up medical
care costs thus tended to be lower for stenting than for conventional
angioplasty ($1918±4841 versus $3359±7100,
P=.21).
Nonetheless, cumulative 1-year medical care costs remained higher for
patients undergoing initial stenting ($11 656±5674 versus
$10 865±9073, P<.001). Even after adjustment for the
higher incidence of vascular complications in the stent group, total
1-year costs were $300 higher for stenting than for balloon
angioplasty.
Conclusions Elective coronary stenting, as performed in
the randomized STRESS trial, increased total 1-year medical care costs
by
$800 per patient compared with conventional angioplasty. Future
studies will be necessary to determine whether ongoing refinements in
stent design, implantation techniques, and anticoagulation regimens can
narrow this cost difference further by reducing stent-related
vascular complications or length of stay.
Key Words: stents angioplasty trials cost-benefit analysis coronary disease
This article has been cited by other articles:
![]() |
D. S. Pinto, G. W. Stone, C. Shi, E. S. Dunn, M. R. Reynolds, M. York, J. Walczak, R. H. Berezin, R. Mehran, B. T. McLaurin, et al. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes. J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1758 - 1768. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-A. Eastwood, L. Doering, J. Roper, and R. D. Hays Uncertainty and Health-Related Quality of Life 1 Year After Coronary Angiography Am. J. Crit. Care., May 1, 2008; 17(3): 232 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Stroupe, D. A. Morrison, M. A. Hlatky, P. G. Barnett, L. Cao, C. Lyttle, D. M. Hynes, W. G. Henderson, and for the Investigators of Veterans Affairs Cooperat Cost-Effectiveness of Coronary Artery Bypass Grafts Versus Percutaneous Coronary Intervention for Revascularization of High-Risk Patients Circulation, September 19, 2006; 114(12): 1251 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Elezi, A. Dibra, U. Folkerts, J. Mehilli, S. Heigl, A. Schomig, and A. Kastrati Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease J. Am. Coll. Cardiol., July 18, 2006; 48(2): 262 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bakhai, G. W. Stone, E. Mahoney, T. A. Lavelle, C. Shi, R. H. Berezin, B. J. Lahue, M. A. Clark, M. J. Lacey, M. E. Russell, et al. Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization: Results From the TAXUS-IV Trial J. Am. Coll. Cardiol., July 18, 2006; 48(2): 253 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, A. M. Lincoff, T. A. Lavelle, H.-L. Chen, A. Bakhai, R. H. Berezin, D. Jackman, I. J. Sarembock, and E. J. Topol Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1792 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, S. A. Murphy, D. S. Baim, T. A. Lavelle, R. H. Berezin, D. E. Cutlip, K. K.L. Ho, R. E. Kuntz, and the SAFER Trial Investigators Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: Results from the SAFER trial J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1801 - 1808. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Hlatky, D. B. Boothroyd, K. A. Melsop, M. M. Brooks, D. B. Mark, B. Pitt, G. S. Reeder, W. J. Rogers, T. J. Ryan, P. L. Whitlow, et al. Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease Circulation, October 5, 2004; 110(14): 1960 - 1966. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, A. Bakhai, C. Shi, L. Githiora, T. Lavelle, R. H. Berezin, M. B. Leon, J. W. Moses, J. P. Carrozza Jr, J. P. Zidar, et al. Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial Circulation, August 3, 2004; 110(5): 508 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Clark, A. Bakhai, M. J. Lacey, E. M. Pelletier, and D. J. Cohen Clinical and Economic Outcomes of Percutaneous Coronary Interventions in the Elderly: An Analysis of Medicare Claims Data Circulation, July 20, 2004; 110(3): 259 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J Nordmann, P. Hengstler, B. M Leimenstoll, T. Harr, J. Young, and H. C Bucher Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: A meta-analysis of randomized controlled trials Eur. Heart J., January 1, 2004; 25(1): 69 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Gray and D. L. Veenstra Comparative economic analyses of minimally invasive direct coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 618 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, R. S. Cosgrove, R. H. Berezin, P. S. Teirstein, M. B. Leon, R. E. Kuntz, and on behalf of the Gamma-1 Investigators Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial Circulation, August 6, 2002; 106(6): 691 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cohen, D. A. Taira, R. Berezin, D. A. Cox, M.-C. Morice, G. W. Stone, and C. L. Grines Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial Circulation, December 18, 2001; 104(25): 3039 - 3045. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rinfret, C. L. Grines, R. S. Cosgrove, K. K. L. Ho, D. A. Cox, B. R. Brodie, M.-C. Morice, G. W. Stone, D. J. Cohen, and the Stent-PAMI Investigators Quality of life after balloon angioplasty or stenting for acute myocardial infarction: One-year results from the Stent-PAMI trial J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1614 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.S. Weintraub Economics of coronary stenting and GPIIb/IIIa blockade Eur. Heart J., August 2, 2001; 22(16): 1366 - 1368. [PDF] |
||||
![]() |
C.V Patil, E Nikolsky, M Boulos, E Grenadier, and R Beyar Multivessel coronary artery disease: current revascularization strategies Eur. Heart J., July 2, 2001; 22(14): 1183 - 1197. [PDF] |
||||
![]() |
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF] |
||||
![]() |
W. J. Cantor, A. S. Hellkamp, E. D. Peterson, J. P. Zidar, P. A. Cowper, M. H. Sketch Jr, J. E. Tcheng, R. M. Califf, and E. M. Ohman Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes? J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1883 - 1890. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Suryapranata, J P Ottervanger, E Nibbering, A W J van't Hof, J C A Hoorntje, M J de Boer, M J Al, and F Zijlstra Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction Heart, June 1, 2001; 85(6): 667 - 671. [Abstract] [Full Text] |
||||
![]() |
P. W. Serruys, B. de Bruyne, S. Carlier, J. E. Sousa, J. Piek, T. Muramatsu, C. Vrints, P. Probst, R. Seabra-Gomes, I. Simpson, et al. Randomized Comparison of Primary Stenting and Provisional Balloon Angioplasty Guided by Flow Velocity Measurement Circulation, December 12, 2000; 102(24): 2930 - 2937. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Cantor, E. D. Peterson, J. J. Popma, J. P. Zidar, M. H. Sketch Jr., J. E. Tcheng, and E. M. Ohman Provisional stenting strategies: systematic overview and implications for clinical decision-making J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1142 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gottsauner-Wolf, G. Zasmeta, S. Hornykewycz, M. Nikfardjam, E. Stepan, P. Wexberg, G. Zorn, D. Glogar, P. Probst, G. Maurer, et al. Plasma levels of C-reactive protein after coronary stent implantation Eur. Heart J., July 2, 2000; 21(14): 1152 - 1158. [Abstract] [PDF] |
||||
![]() |
D. E. Cutlip, M. B. Leon, K. K. L. Ho, P. C. Gordon, A. Giambartolomei, D. J. Diver, D. M. Lasorda, D. O. Williams, M. M. Fitzpatrick, A. Desjardin, et al. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: Results from the STent anti-thrombotic regimen study (STARS) registry J. Am. Coll. Cardiol., September 1, 1999; 34(3): 698 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Peterson, P. A. Cowper, E. R. DeLong, J. P. Zidar, R. S. Stack, and D. B. Mark Acute and long-term cost implications of coronary stenting J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1610 - 1618. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Leon, D. S. Baim, J. J. Popma, P. C. Gordon, D. E. Cutlip, K. K.L. Ho, A. Giambartolomei, D. J. Diver, D. M. Lasorda, D. O. Williams, et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting N. Engl. J. Med., December 3, 1998; 339(23): 1665 - 1671. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Holmes Jr., J. Hirshfeld Jr., D. Faxon, R. Vlietstra, A. Jacobs, S. B. King III, T. M. Bashore, N. D. Bridges, C. B. Higgins, L. F. Hiratzka, et al. ACC expert consensus document on coronary artery stents: Document of the American College of Cardiology J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1471 - 1482. [Full Text] [PDF] |
||||
![]() |
H S Lee, C Densem, R D Levy, D H Bennett, S G Ray, and N H Brooks Impact of stenting on coronary angioplasty procedures Heart, November 1, 1998; 80(5): 505 - 508. [Abstract] [Full Text] |
||||
![]() |
P. A. Sirnes, S. Golf, Y. Myreng, P. Molstad, P. Albertsson, A. Mangschau, K. Endresen, and J. Kjekshus Sustained benefit of stenting chronic coronary occlusion: long-term clinical follow-up of the Stenting in Chronic Coronary Occlusion (SICCO) study J. Am. Coll. Cardiol., August 1, 1998; 32(2): 305 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Narins, D. R. Holmes Jr, and E. J. Topol A Call for Provisional Stenting : The Balloon Is Back! Circulation, April 7, 1998; 97(13): 1298 - 1305. [Full Text] [PDF] |
||||
![]() |
I. Moussa, B. Reimers, J. Moses, C. Di Mario, L. Di Francesco, M. Ferraro, and A. Colombo Long-term Angiographic and Clinical Outcome of Patients Undergoing Multivessel Coronary Stenting Circulation, December 2, 1997; 96(11): 3873 - 3879. [Abstract] [Full Text] |
||||
![]() |
D. S. Baim and J. P. Carrozza Jr Stent Thrombosis: Closing in on the Best Preventive Treatment Circulation, March 4, 1997; 95(5): 1098 - 1100. [Full Text] |
||||
![]() |
D. O. Williams Dressing Up the Palmaz-Schatz Stent Circulation, February 1, 1996; 93(3): 400 - 402. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |